ESGBERT/base_data · Datasets at Hugging Face

sentence stringlengths 1 23.5k ⌀
\| P A G E Elanco Animal Health Incorporated (NYSE: ELAN) is a global animal health company that develops products and knowledge services to prevent and treat disease in food animals and pets in more than 90 countries.
With a rigorously innovate to improve the health of animals and benefit our customers, while fostering an inclusive, cause-driven culture for more than 5,800 employees.
As pets increasingly become important parts of our families, the need to help them live longer, healthier, higher quality lives increase as well.
As the global population grows, so too will the need to meet the demand for safe, affordable food for all.
At Elanco, we’re driven by our vision of food and companionship enriching life–all to advance the health of animals, people, and the planet.
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world.
DELIVERING VALUE AND REDUCING COSTS In Health subsidiary with an initial public offering and divestiture.
This transaction allows Lilly to focus exclusively on human medicines—discovering, developing, manufacturing and reaching patients with new therapies for serious health conditions.
In the past five years, we have launched to our goal of 20 new molecules by 2023.
The initially promising results of one of those medicines, Lartruvo for soft tissue sarcoma, were not confirmed in later clinical trials—a risk inherent in the scientific process.
So Lilly worked quickly with regulators to develop a plan to withdraw Lartruvo from the market while allowing current patients to continue receiving therapy.
Growing numbers of people are benefiting from Lilly’s medicines around the world.
Still, we recognize that the cost of medicines is a concern for many, and sometimes an obstacle to people getting treatment.
That’s why Lilly has a long-standing policy of not seeking or enforcing patents for medicines in any of the “least developed countries,” as defined by the United Nations.
It’s also why we’re working with others in the U.S. healthcare system to make sure patients can get the medicines they need—at reasonable out-of-pocket costs and with pricing information they can understand.
In opened the Lilly Diabetes Solution Center to assist people who need help paying for their Lilly insulin.
We also launched Insulin Lispro, an authorized generic insulin, at a list price insulin, Humalog.
We know there’s more to do, and we are committed to working with others across healthcare systems to advocate for policies that expand access to medicines while rewarding innovation.
To support our strategy of innovation, we must have a culture of diversity and inclusion (D&I)—one in which everyone can bring diverse ideas, perspectives, and experiences to bear in the pursuit of our purpose.
We’ve taken a research-based approach—modeled after the research we conduct to understand our own patient populations.
This research has helped us better understand the experiences, unmet needs, and career tensions of our employees, especially women and minorities, and informed companywide D&I programs.
From the end of the number of women in management globally to 42 percent, our initial aspirational goal.
This year, we set even higher aspirational goals for women and minorities in management.
In early D A V I D A .
At Eli Lilly and Company, our purpose is to unite caring with discovery to create medicines that make life better for people around the world.
Core to our purpose is our commitment to aid human suffering—independent of an individual’s or nation’s economic status—and to conduct our business in a responsible way for the long term.
\| P A G E we were proud that our research-based approach was recognized with the prestigious Catalyst Award—one of four companies to receive this honor this year—reflecting our D&I focus.
Advances in healthcare have helped billions live longer lives.
But in too many places around the world, due to insufficient development of healthcare systems, these innovations are out of reach.
Lilly has set a goal to create new access to quality health care in resourcelimited settings for 2030.
It focuses on three areas: health systems; 2) Programs—enhancing access to Lilly medicines; and 3) Pipeline—finding molecules for diseases that disproportionately affect people in resource-limited settings.
In AMPATH, a medical consortium making an incredible difference in the lives of patients in western Kenya who are in desperate need.
Since nearly $150 million in product donations to AMPATH, helping to dramatically reduce what were once frequent shortages of medicine.
The Lilly Foundation has committed an additional $expand its breast and cervical cancer screenings— including mobile outreach for rural areas.
In health programs, we gathered with local partners to launch a program addressing health disparities in our own hometown of Indianapolis.
The result is a neighborhood-based approach designed to help address the high incidence of diabetes in three Indianapolis communities—where life expectancy can be lower than in neighborhoods just 10 miles away.
The $community healthcare workers who help identify people with diabetes and connect them with quality care.
In the next few years, we will focus even more on the areas of programs and pipeline to increase our impact.
MANAGING OUR ENVIRONMENTAL IMPACTS Lilly is committed to continually reducing our environmental footprint and to publicly reporting progress toward our goals.
In (formerly Carbon Disclosure Project) score of A- on climate change, which is considered leadership level, and we received a B on water stewardship.
As of the end of goals: achieving a 20 percent improvement in our waste efficiency, and a 15 percent reduction in phosphorous emissions in wastewater.
By tests—a mandatory quality test for pharmaceuticals and medical devices—from a process which relies on bleeding horseshoe crabs, to a synthetic compound.
This new method, which Lilly helped to validate, is equally effective, more efficient, and cost-effective—and it doesn’t require harvesting live animals.
Transitioning our testing will lessen our impacts on the wild crab population, reducing our dependence on an increasingly at-risk species that is a vital part of many food webs, including for endangered and threatened birds.
Every day, Lilly’s team of of integrity, excellence, and respect for people.
While pleased with our performance, we are not satisfied.
\| P A G E Lilly has a long, proud heritage of strengthening the communities where we work and live.
We do this through giving, volunteering, and focusing on the issues that tie back to our business: health and education.
Connecting Hearts Abroad More than through Connecting Hearts Abroad, our global service program.
Working on health and community projects across Africa, Asia, Europe, and Latin America, volunteers return to Lilly with insights that help us become a better, more globally aware company.
In of Service, on which Lilly and Elanco employees help neighbors and communities around the world.
Since the program launched, employees in over have given more than 1 million hours and created a lasting legacy by completing thousands of projects— from assembling cancer-care packages for patients to beautifying neighborhoods by planting thousands of trees.
United Way In relationship dating back to 1918.
To date, Lilly has raised more than $300 million for United Way.
\| P A G E The Lilly Foundation works to improve the lives of those who lack resources, including supporting and championing efforts in our home state of Indiana to strengthen public education focusing on early childhood education, K-12, and STEM subjects (science, technology, engineering, and math).
We also discuss data and trends from previous years, where relevant, and include some significant events and initiatives that occurred in the first half of 2019.
In September an initial public offering (IPO) of Elanco Animal Health Incorporated (NYSE: ELAN), thereby making it an independently traded company.
Elanco, previously a division of Lilly, is a global animal health company that develops products and knowledge services to prevent and treat disease in food animals and pets.
This report includes data from Elanco through period immediately following its IPO.
ERM Certification and Verification Services provided independent, third-party verification on selected environmental data and progress against selected goals as described in the assurance statement.
For example, following guidance from the World Resources Institute, we report progress toward greenhouse gas emissions goals on an adjusted basis accounting for mergers, acquisitions, and divestitures as appropriate, to ensure comparability, unless stated otherwise.
\| P A G E As a member of the UN Global Compact, Eli Lilly supports the United Nation’s Sustainable Development Goals (SDGs) and works to advance these goals within our sphere of influence.
A G E Lilly has a longstanding commitment to bioethics—which focuses on the ethics of health care, biomedical research, and biomedical public policy—as an integral component of corporate integrity in the pharmaceutical industry.
In became one of the first pharmaceutical companies to establish a standing bioethics committee to systematically identify, evaluate, and communicate bioethics issues, and in 2008 created a bioethics program with dedicated full-time staff.
Bioethics at Lilly Consolidating the company’s ethics efforts under one tent, in early within the Global Ethics and Compliance organization, reporting to the chief ethics and compliance officer.
This move increases the independence of the bioethics function overall and allows the bioethics team broader focus across all aspects of Lilly’s operations—from research and development to commercialization activities.
Bioethics team members include full-time, dedicated staff with pharmaceutical industry expertise as well as specialized training in bioethics.
These individuals serve as valuable internal resources for the company, and are responsible for the program’s development, deliverables, and oversight.
A cross-functional bioethics advisory committee also includes external expertise in bioethics.
Moving Lilly’s bioethics program within our Global Ethics and Compliance organization will continue to elevate this important work and enable greater engagement—beyond just clinical research—with all facets of our enterprise.
This move is part of our ongoing efforts to reflect our commitment to integrity and to engrain ethical decision-making into every phase of our work.
A G E Protecting Research Subjects’ Rights in Clinical Trials Lilly is committed to protecting the rights and well-being of research subjects and patients who use our medicines.
LILLY’S PRINCIPLES OF MEDICAL RESEARCH The Principles of Medical Research specify Lilly’s standard for conducting, funding, and communicating results from its medical research.
Lilly’s Bioethics Framework for Human Biomedical Research provides a bioethics foundation for the company’s biomedical research so that it is aligned with broadly accepted ethics principles and Lilly’s core values.
The framework informs the development of bioethics positions on topics important to pharmaceutical research and development, and it informs advice that the bioethics committee provides.
Lilly has developed position statements on bioethics issues such as stem cell research, pediatric medicine, and multinational clinical trials, among others.
Since an internal consulting service, providing a forum for employees to seek advice regarding bioethics and research ethics issues.
A G E We work tirelessly to make our medications safe and effective—from the early stages of design and drug development— through ongoing monitoring and understanding of the patient experience once a medication is on the market.
Lilly’s Global Patient Safety organization— consisting of more than nurses, and other healthcare professionals—is dedicated to the continuous collection, monitoring, evaluation, and reporting of safety information.
Before they enter the Lilly system, our raw material and component suppliers are evaluated for technical competence, and the ability to provide highquality, efficacious, and cost-effective raw materials to Lilly.
The introduction of product serialization, first rolled out in the United States in to follow, adds an additional level of security to our distributed products.
A G E At Lilly, our efforts to ensure the safety and integrity of our products begin with the procurement of materials and extend throughout the production process.
This includes our interactions to promote strong health, safety, and environment (HSE) practices with suppliers who provide us materials for research and development, as well as with the contract manufacturers who help make our medicines and other pharmaceutical products.
Their impact is wide-reaching and potentially deadly, both due to toxic substances sometimes found in the counterfeit medicines, and because they undermine a patient’s confidence in legitimate medicines and the credibility of healthcare providers.
AND IN THE FIELD Patient safety is the foundation of Lilly’s global anticounterfeiting efforts, and we are engaged in efforts to combat counterfeiters.
We are a founder and member of the Alliance for Safe Online Pharmacies, a global coalition of stakeholders with an interest in protecting patient safety and ensuring patients have access to safe and legitimate online pharmacies.
SERIALIZATION Serialization is the unique identification of individual packs of medicines to ensure the security of the legitimate supply chain.
Lilly has made considerable investments in its packaging operations, distribution centers, and IT infrastructure to support this initiative, including new technology, which impacts all of our packaging lines around the world.
Lilly believes that it is imperative that legislative efforts and policies around serialization and product traceability follow global standards.
Non-standard requirements not only increase the implementation costs for manufacturers and trading partners, but also fail to adequately prevent counterfeit products from entering the legitimate supply chain, increasing the potential for patient harm.
A G E in many markets around the world to advocate for global standards to ensure a harmonized approach to product traceability initiatives.
We played a leadership role in China on this issue, influencing a shift from a nonstandard product traceability requirement to a policy that will accommodate global standards.
In Malaysia and India, Lilly is investing in advocacy to educate and inform regulatory authorities on the importance of adhering to global standards as they evaluate upcoming legislation.
From U.S. Securities and Exchange Commission (SEC) relating to the conflict minerals rule.
A G E Our efforts to bring innovative medicines to patients may take different paths depending on the healthcare system unique to a specific region of the world.
Lilly works across the healthcare system to find solutions that make medicines more accessible.
This includes innovating beyond the medicines we produce.
The future of the healthcare system depends on how well it works for patients.
Lilly remains committed to supporting a system that enables people to live longer, healthier, more active lives.
Lilly sells medicines in approximately around the world.

| P A G E Elanco Animal Health Incorporated (NYSE: ELAN) is a global animal health company that develops products and knowledge services to prevent and treat disease in food animals and pets in more than 90 countries.

With a rigorously innovate to improve the health of animals and benefit our customers, while fostering an inclusive, cause-driven culture for more than 5,800 employees.

As pets increasingly become important parts of our families, the need to help them live longer, healthier, higher quality lives increase as well.

As the global population grows, so too will the need to meet the demand for safe, affordable food for all.

At Elanco, we’re driven by our vision of food and companionship enriching life–all to advance the health of animals, people, and the planet.

Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world.

DELIVERING VALUE AND REDUCING COSTS In Health subsidiary with an initial public offering and divestiture.

This transaction allows Lilly to focus exclusively on human medicines—discovering, developing, manufacturing and reaching patients with new therapies for serious health conditions.

In the past five years, we have launched to our goal of 20 new molecules by 2023.

The initially promising results of one of those medicines, Lartruvo for soft tissue sarcoma, were not confirmed in later clinical trials—a risk inherent in the scientific process.

So Lilly worked quickly with regulators to develop a plan to withdraw Lartruvo from the market while allowing current patients to continue receiving therapy.

Growing numbers of people are benefiting from Lilly’s medicines around the world.

Still, we recognize that the cost of medicines is a concern for many, and sometimes an obstacle to people getting treatment.

That’s why Lilly has a long-standing policy of not seeking or enforcing patents for medicines in any of the “least developed countries,” as defined by the United Nations.

It’s also why we’re working with others in the U.S. healthcare system to make sure patients can get the medicines they need—at reasonable out-of-pocket costs and with pricing information they can understand.

In opened the Lilly Diabetes Solution Center to assist people who need help paying for their Lilly insulin.

We also launched Insulin Lispro, an authorized generic insulin, at a list price insulin, Humalog.

We know there’s more to do, and we are committed to working with others across healthcare systems to advocate for policies that expand access to medicines while rewarding innovation.

To support our strategy of innovation, we must have a culture of diversity and inclusion (D&I)—one in which everyone can bring diverse ideas, perspectives, and experiences to bear in the pursuit of our purpose.

We’ve taken a research-based approach—modeled after the research we conduct to understand our own patient populations.

This research has helped us better understand the experiences, unmet needs, and career tensions of our employees, especially women and minorities, and informed companywide D&I programs.

From the end of the number of women in management globally to 42 percent, our initial aspirational goal.

This year, we set even higher aspirational goals for women and minorities in management.

In early D A V I D A .

At Eli Lilly and Company, our purpose is to unite caring with discovery to create medicines that make life better for people around the world.

Core to our purpose is our commitment to aid human suffering—independent of an individual’s or nation’s economic status—and to conduct our business in a responsible way for the long term.

| P A G E we were proud that our research-based approach was recognized with the prestigious Catalyst Award—one of four companies to receive this honor this year—reflecting our D&I focus.

Advances in healthcare have helped billions live longer lives.

But in too many places around the world, due to insufficient development of healthcare systems, these innovations are out of reach.

Lilly has set a goal to create new access to quality health care in resourcelimited settings for 2030.

It focuses on three areas: health systems; 2) Programs—enhancing access to Lilly medicines; and 3) Pipeline—finding molecules for diseases that disproportionately affect people in resource-limited settings.

In AMPATH, a medical consortium making an incredible difference in the lives of patients in western Kenya who are in desperate need.

Since nearly $150 million in product donations to AMPATH, helping to dramatically reduce what were once frequent shortages of medicine.

The Lilly Foundation has committed an additional $expand its breast and cervical cancer screenings— including mobile outreach for rural areas.

In health programs, we gathered with local partners to launch a program addressing health disparities in our own hometown of Indianapolis.

The result is a neighborhood-based approach designed to help address the high incidence of diabetes in three Indianapolis communities—where life expectancy can be lower than in neighborhoods just 10 miles away.

The $community healthcare workers who help identify people with diabetes and connect them with quality care.

In the next few years, we will focus even more on the areas of programs and pipeline to increase our impact.

MANAGING OUR ENVIRONMENTAL IMPACTS Lilly is committed to continually reducing our environmental footprint and to publicly reporting progress toward our goals.

In (formerly Carbon Disclosure Project) score of A- on climate change, which is considered leadership level, and we received a B on water stewardship.

As of the end of goals: achieving a 20 percent improvement in our waste efficiency, and a 15 percent reduction in phosphorous emissions in wastewater.

By tests—a mandatory quality test for pharmaceuticals and medical devices—from a process which relies on bleeding horseshoe crabs, to a synthetic compound.

This new method, which Lilly helped to validate, is equally effective, more efficient, and cost-effective—and it doesn’t require harvesting live animals.

Transitioning our testing will lessen our impacts on the wild crab population, reducing our dependence on an increasingly at-risk species that is a vital part of many food webs, including for endangered and threatened birds.

Every day, Lilly’s team of of integrity, excellence, and respect for people.

While pleased with our performance, we are not satisfied.

| P A G E Lilly has a long, proud heritage of strengthening the communities where we work and live.

We do this through giving, volunteering, and focusing on the issues that tie back to our business: health and education.

Connecting Hearts Abroad More than through Connecting Hearts Abroad, our global service program.

Working on health and community projects across Africa, Asia, Europe, and Latin America, volunteers return to Lilly with insights that help us become a better, more globally aware company.

In of Service, on which Lilly and Elanco employees help neighbors and communities around the world.

Since the program launched, employees in over have given more than 1 million hours and created a lasting legacy by completing thousands of projects— from assembling cancer-care packages for patients to beautifying neighborhoods by planting thousands of trees.

United Way In relationship dating back to 1918.

To date, Lilly has raised more than $300 million for United Way.

| P A G E The Lilly Foundation works to improve the lives of those who lack resources, including supporting and championing efforts in our home state of Indiana to strengthen public education focusing on early childhood education, K-12, and STEM subjects (science, technology, engineering, and math).

We also discuss data and trends from previous years, where relevant, and include some significant events and initiatives that occurred in the first half of 2019.

In September an initial public offering (IPO) of Elanco Animal Health Incorporated (NYSE: ELAN), thereby making it an independently traded company.

Elanco, previously a division of Lilly, is a global animal health company that develops products and knowledge services to prevent and treat disease in food animals and pets.

This report includes data from Elanco through period immediately following its IPO.

ERM Certification and Verification Services provided independent, third-party verification on selected environmental data and progress against selected goals as described in the assurance statement.

For example, following guidance from the World Resources Institute, we report progress toward greenhouse gas emissions goals on an adjusted basis accounting for mergers, acquisitions, and divestitures as appropriate, to ensure comparability, unless stated otherwise.

| P A G E As a member of the UN Global Compact, Eli Lilly supports the United Nation’s Sustainable Development Goals (SDGs) and works to advance these goals within our sphere of influence.

A G E Lilly has a longstanding commitment to bioethics—which focuses on the ethics of health care, biomedical research, and biomedical public policy—as an integral component of corporate integrity in the pharmaceutical industry.

In became one of the first pharmaceutical companies to establish a standing bioethics committee to systematically identify, evaluate, and communicate bioethics issues, and in 2008 created a bioethics program with dedicated full-time staff.

Bioethics at Lilly Consolidating the company’s ethics efforts under one tent, in early within the Global Ethics and Compliance organization, reporting to the chief ethics and compliance officer.

This move increases the independence of the bioethics function overall and allows the bioethics team broader focus across all aspects of Lilly’s operations—from research and development to commercialization activities.

Bioethics team members include full-time, dedicated staff with pharmaceutical industry expertise as well as specialized training in bioethics.

These individuals serve as valuable internal resources for the company, and are responsible for the program’s development, deliverables, and oversight.

A cross-functional bioethics advisory committee also includes external expertise in bioethics.

Moving Lilly’s bioethics program within our Global Ethics and Compliance organization will continue to elevate this important work and enable greater engagement—beyond just clinical research—with all facets of our enterprise.

This move is part of our ongoing efforts to reflect our commitment to integrity and to engrain ethical decision-making into every phase of our work.

A G E Protecting Research Subjects’ Rights in Clinical Trials Lilly is committed to protecting the rights and well-being of research subjects and patients who use our medicines.

LILLY’S PRINCIPLES OF MEDICAL RESEARCH The Principles of Medical Research specify Lilly’s standard for conducting, funding, and communicating results from its medical research.

Lilly’s Bioethics Framework for Human Biomedical Research provides a bioethics foundation for the company’s biomedical research so that it is aligned with broadly accepted ethics principles and Lilly’s core values.

The framework informs the development of bioethics positions on topics important to pharmaceutical research and development, and it informs advice that the bioethics committee provides.

Lilly has developed position statements on bioethics issues such as stem cell research, pediatric medicine, and multinational clinical trials, among others.

Since an internal consulting service, providing a forum for employees to seek advice regarding bioethics and research ethics issues.

A G E We work tirelessly to make our medications safe and effective—from the early stages of design and drug development— through ongoing monitoring and understanding of the patient experience once a medication is on the market.

Lilly’s Global Patient Safety organization— consisting of more than nurses, and other healthcare professionals—is dedicated to the continuous collection, monitoring, evaluation, and reporting of safety information.

Before they enter the Lilly system, our raw material and component suppliers are evaluated for technical competence, and the ability to provide highquality, efficacious, and cost-effective raw materials to Lilly.

The introduction of product serialization, first rolled out in the United States in to follow, adds an additional level of security to our distributed products.

A G E At Lilly, our efforts to ensure the safety and integrity of our products begin with the procurement of materials and extend throughout the production process.

This includes our interactions to promote strong health, safety, and environment (HSE) practices with suppliers who provide us materials for research and development, as well as with the contract manufacturers who help make our medicines and other pharmaceutical products.

Their impact is wide-reaching and potentially deadly, both due to toxic substances sometimes found in the counterfeit medicines, and because they undermine a patient’s confidence in legitimate medicines and the credibility of healthcare providers.

AND IN THE FIELD Patient safety is the foundation of Lilly’s global anticounterfeiting efforts, and we are engaged in efforts to combat counterfeiters.

We are a founder and member of the Alliance for Safe Online Pharmacies, a global coalition of stakeholders with an interest in protecting patient safety and ensuring patients have access to safe and legitimate online pharmacies.

SERIALIZATION Serialization is the unique identification of individual packs of medicines to ensure the security of the legitimate supply chain.

Lilly has made considerable investments in its packaging operations, distribution centers, and IT infrastructure to support this initiative, including new technology, which impacts all of our packaging lines around the world.

Lilly believes that it is imperative that legislative efforts and policies around serialization and product traceability follow global standards.

Non-standard requirements not only increase the implementation costs for manufacturers and trading partners, but also fail to adequately prevent counterfeit products from entering the legitimate supply chain, increasing the potential for patient harm.

A G E in many markets around the world to advocate for global standards to ensure a harmonized approach to product traceability initiatives.

We played a leadership role in China on this issue, influencing a shift from a nonstandard product traceability requirement to a policy that will accommodate global standards.

In Malaysia and India, Lilly is investing in advocacy to educate and inform regulatory authorities on the importance of adhering to global standards as they evaluate upcoming legislation.

From U.S. Securities and Exchange Commission (SEC) relating to the conflict minerals rule.

A G E Our efforts to bring innovative medicines to patients may take different paths depending on the healthcare system unique to a specific region of the world.

Lilly works across the healthcare system to find solutions that make medicines more accessible.

This includes innovating beyond the medicines we produce.

The future of the healthcare system depends on how well it works for patients.

Lilly remains committed to supporting a system that enables people to live longer, healthier, more active lives.

Lilly sells medicines in approximately around the world.